Tianyao Yang, Chunyan Chen, Fangfang Wang, Lan Yue
{"title":"n7 -甲基鸟苷(m7G)修饰在乳腺癌中的临床意义及分子机制","authors":"Tianyao Yang, Chunyan Chen, Fangfang Wang, Lan Yue","doi":"10.1186/s12935-025-03859-y","DOIUrl":null,"url":null,"abstract":"<p><p>The therapeutic strategies for advanced breast cancer (BC) continue to present significant challenges. Consequently, the implementation of precise diagnostic biomarkers and prognostic targets is essential for effective BC management. Recently, N7-methylguanosine (m7G) modification has garnered considerable attention in the context of various cancer types. In this study, we conducted a comprehensive literature review to explore the potential role of m7G in the tumorigenesis of BC. Analysis of thirteen relevant studies revealed that m7G methyltransferases were usually aberrantly expressed in BC, including TNBC and breast invasive carcinoma. m7G modifications in mRNA, tRNA, and rRNA can ultimately affect the expression of target genes (i.e., m7G regulators [e.g., METTL1/WDR4], m7G-associated genes [e.g. P27 and AGO2], m7G-related lncRNAs [e.g., LINC01871 and LINC00115], and m7G-related miRNAs [e.g. miR-7 and miR-139]) and regulate BC-related biological functions. These novel insights indicate that m7G modification and its regulators hold significant potential for future clinical applications in the diagnosis and treatment of BC. In the future, how to apply m7G modifications to identify the implementation of clinically personalized BC treatment needs to be further explored.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"303"},"PeriodicalIF":6.0000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341331/pdf/","citationCount":"0","resultStr":"{\"title\":\"N7-methylguanosine (m7G) modification in breast cancer: clinical significances and molecular mechanisms.\",\"authors\":\"Tianyao Yang, Chunyan Chen, Fangfang Wang, Lan Yue\",\"doi\":\"10.1186/s12935-025-03859-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The therapeutic strategies for advanced breast cancer (BC) continue to present significant challenges. Consequently, the implementation of precise diagnostic biomarkers and prognostic targets is essential for effective BC management. Recently, N7-methylguanosine (m7G) modification has garnered considerable attention in the context of various cancer types. In this study, we conducted a comprehensive literature review to explore the potential role of m7G in the tumorigenesis of BC. Analysis of thirteen relevant studies revealed that m7G methyltransferases were usually aberrantly expressed in BC, including TNBC and breast invasive carcinoma. m7G modifications in mRNA, tRNA, and rRNA can ultimately affect the expression of target genes (i.e., m7G regulators [e.g., METTL1/WDR4], m7G-associated genes [e.g. P27 and AGO2], m7G-related lncRNAs [e.g., LINC01871 and LINC00115], and m7G-related miRNAs [e.g. miR-7 and miR-139]) and regulate BC-related biological functions. These novel insights indicate that m7G modification and its regulators hold significant potential for future clinical applications in the diagnosis and treatment of BC. In the future, how to apply m7G modifications to identify the implementation of clinically personalized BC treatment needs to be further explored.</p>\",\"PeriodicalId\":9385,\"journal\":{\"name\":\"Cancer Cell International\",\"volume\":\"25 1\",\"pages\":\"303\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2025-08-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341331/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Cell International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12935-025-03859-y\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12935-025-03859-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
N7-methylguanosine (m7G) modification in breast cancer: clinical significances and molecular mechanisms.
The therapeutic strategies for advanced breast cancer (BC) continue to present significant challenges. Consequently, the implementation of precise diagnostic biomarkers and prognostic targets is essential for effective BC management. Recently, N7-methylguanosine (m7G) modification has garnered considerable attention in the context of various cancer types. In this study, we conducted a comprehensive literature review to explore the potential role of m7G in the tumorigenesis of BC. Analysis of thirteen relevant studies revealed that m7G methyltransferases were usually aberrantly expressed in BC, including TNBC and breast invasive carcinoma. m7G modifications in mRNA, tRNA, and rRNA can ultimately affect the expression of target genes (i.e., m7G regulators [e.g., METTL1/WDR4], m7G-associated genes [e.g. P27 and AGO2], m7G-related lncRNAs [e.g., LINC01871 and LINC00115], and m7G-related miRNAs [e.g. miR-7 and miR-139]) and regulate BC-related biological functions. These novel insights indicate that m7G modification and its regulators hold significant potential for future clinical applications in the diagnosis and treatment of BC. In the future, how to apply m7G modifications to identify the implementation of clinically personalized BC treatment needs to be further explored.
期刊介绍:
Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques.
The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors.
Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.